Eye Drop Instillation of the Rac1 Modulator CNF1 Attenuates Retinal Gliosis and Ameliorates Visual Performance in a Rat Model of Hypertensive Retinopathy

Research output: Contribution to journalArticlepeer-review

Abstract

In hypertensive retinopathy, the retinal damage due to high blood pressure is accompanied by increased expression of Glial Fibrillary Acidic Protein (GFAP), which indicates a role of neuroinflammatory processes in such a retinopathy. Proteins belonging to the Rho GTPase family, particularly Rac1, are involved in the activation of Müller glia and in the progression of photoreceptor degeneration, and may thus represent a novel candidate for therapeutic intervention following central nervous system inflammation. In this paper, we have observed that topical administration as eye drops of Cytotoxic Necrotizing Factor 1 (CNF1), a Rho GTPase modulator, surprisingly improves electrophysiological and behavioral visual performances in aged spontaneously hypertensive rats. Furthermore, such functional improvement is accompanied by a reduction of Rac1 activity and retinal GFAP expression. Our results suggest that Rac1 inhibition through CNF1 topical administration may represent a new strategy to target retinal gliosis.

Original languageEnglish
Pages (from-to)119-129
Number of pages11
JournalNeuroscience
Volume411
DOIs
Publication statusPublished - Jul 15 2019

Keywords

  • Animals
  • Bacterial Toxins/administration & dosage
  • Disease Models, Animal
  • Escherichia coli Proteins/administration & dosage
  • Gliosis/drug therapy
  • Hypertensive Retinopathy/drug therapy
  • Male
  • Ophthalmic Solutions
  • Rats
  • Rats, Inbred SHR
  • Retina/drug effects
  • Vision, Ocular/drug effects

Fingerprint Dive into the research topics of 'Eye Drop Instillation of the Rac1 Modulator CNF1 Attenuates Retinal Gliosis and Ameliorates Visual Performance in a Rat Model of Hypertensive Retinopathy'. Together they form a unique fingerprint.

Cite this